The Filing Desk

Castle Biosciences

CSTL · Nasdaq · Health Care · Financials, fiscal 2018 to 2025

CSTL · Last close · November 13, 2026
$33.79
Value Castle Biosciences yourself

Castle Biosciences' revenue rose 3.7% to $344 million in fiscal 2025. Its operating margin was −12.4%, down from 2.6% a year earlier. Free cash flow was $28 million, down 22.5%. The diluted share count fell 0.9%.

CASTLE BIOSCIENCES, INC. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001628280-26-012272 Updated
Revenue
$344M
3.7%
Operating margin
−12.4%
15.0 pts
Net income
−$24M
$18M a year earlier
Free cash flow
$28M
22.5%
Return on capital
−19.1%
23.6 pts
Market cap
$1.0B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Net debt to EBITDA for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Castle Biosciences does

Castle Biosciences runs genetic and molecular tests on patient samples to help doctors decide how to diagnose and treat certain illnesses. Its tests cover skin cancers, Barrett's esophagus (a condition in the food pipe that can lead to cancer), eczema (atopic dermatitis) and eye melanoma. Its customers are the doctors who order the tests.

Its main tests are DecisionDx-Melanoma, which estimates the risk that a melanoma skin cancer will spread or come back, TissueCypher, which estimates the risk that Barrett's esophagus will progress to cancer, and DecisionDx-SCC for another skin cancer. It also sells DecisionDx-UM and MyPath Melanoma. In November 2025 it began a limited launch of AdvanceAD-Tx, a test that helps pick treatment for moderate-to-severe eczema. Castle says about 158 peer-reviewed articles support its tests.

Castle gets paid for its tests by insurers and Medicare, so whether they cover the tests matters a great deal to it. In 2025 it bought a company called Previse, which has technology for collecting esophageal cells without an endoscope, the camera procedure doctors normally use. Castle has lost money in the past.

Its biggest risks, as it describes them

  • A large share of its revenue comes from a small number of insurers and other payors.
  • Depending mainly on three tests, DecisionDx-Melanoma, TissueCypher and DecisionDx-SCC, for its revenue.
  • Medicare coverage decisions for its tests, including reconsideration requests that are still pending.
  • Billing for its tests is complex and takes time and resources to collect.
  • Past losses, possible need for more capital, and loan terms that limit what it can do.
From Castle Biosciences's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Castle Biosciences lost money in fiscal 2025: a net loss of $24 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments330259243293300
Debt incl. finance leases0001010
Net debt (negative means net cash)−329−258−243−283−289
Net debt to EBITDA———−11.5x—
Debt to equity0.0x0.0x0.0x0.0x0.0x
Interest coverage−40,079.0x−4,285.6x−6,179.7x15.0x−497.8x
Current ratio14.2x8.1x6.2x7.3x5.3x
Quick ratio14.1x8.0x6.0x7.1x5.1x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Castle Biosciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Castle Biosciences says to expect

  • Full year 2026: total revenueThe Company now anticipates generating between $385-395 million in total revenue in 2026, compared to the previously provided guidance of between $365-375 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Castle Biosciences reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 97 of 94 of 9
Rule of 4051.6%62.1%11.9%
Altman Z''7.639.076.15
Accruals ratio−11.5%−9.5%−15.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassFail
Cash from operations is positiveFailPassPass
Return on assets rosePassPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailPass
Current ratio roseFailPassFail
Share count didn't riseFailFailPass
Gross margin rosePassPassFail
Revenue rose relative to assetsPassPassFail
F-score4 of 97 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Castle Biosciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Castle BiosciencesFY253.7%−12.4%8.2%−19.1%—4
CareDxFY2513.8%−8.1%—−20.0%—4Compare
GeneDxFY2540.0%−3.1%3.3%−5.3%—6Compare
SchrödingerFY2523.3%−65.2%4.9%———Compare
Starling OncologyFY2527.8%−7.2%−5.5%−75.7%—3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

8 years of figures

Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue23526394137220332344
Revenue growth—127.6%20.8%50.2%45.6%60.4%51.1%3.7%
Gross profit18455378105175272273
Research and development57133045545252
Operating income−47−6−40−73−689−43
Net income−65−10−31−67−5818−24
Diluted EPS (US$)−5.33−0.21−0.54−1.24−2.58−2.140.62−0.83
Diluted shares (millions)29192526272929
Cash flow
Cash from operations−12710−19−42−66564
Capital expenditure01546142836
Free cash flow−1365−22−47−193728
Dividends paid00000000
Share buybacks00000000
Acquisitions000027000
Stock-based compensation0182236515046
Balance sheet at fiscal year end
Cash and short-term investments499410330259243293300
Debt incl. finance leases242700001010
Total assets22120439463447453531579
Total liabilities32352451486275108
Shareholders' equity−5785416412399391456471
Margins and ratios
Gross margin76.8%85.9%84.5%83.2%76.6%79.5%81.9%79.4%
Operating margin−16.8%14.1%−10.4%−42.6%−53.2%−30.9%2.6%−12.4%
Net margin−27.9%10.2%−16.4%−33.3%−49.0%−26.1%5.5%−7.0%
Free cash flow margin−55.2%11.7%8.2%−23.9%−34.5%−8.8%11.0%8.2%
Rule of 40 (growth + FCF margin)—139.3%29.0%26.3%11.2%51.6%62.1%11.9%
Return on capital————−51.6%−37.2%4.6%−19.1%
Return on equity—37.0%−4.1%−7.6%−16.6%−14.5%4.3%−5.2%
Return on assets—7.4%−3.7%−6.9%−14.8%−12.8%3.7%−4.3%
Net debt to EBITDA—−9.4x————−11.5x—
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Castle Biosciences' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Castle Biosciences.